HopeStage
Back to all studies
CompletedNCT00646581

Single-dose insulin for memory and attention in schizophrenia

About this titleRead the official source — NCT00646581
Medication studyAges 18–65United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
BostonSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateOctober 2006
Recruitment status
Completed
Enrollment listed in the registry
30
Sponsor
University of Massachusetts, Worcester
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT00646581
Official title
Show the full official title

Effect of Single Dose Intranasal Insulin on Cognitive Function in Patients With Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Boston

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University of Massachusetts, Worcester, a university.

Did this study involve medication?

Yes. The study involved medication, including Placebo and Insulin (Humulin).

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies